リニカル（2183）のセグメントごとの売上高・利益等
セグメント通期
- 【有報】
- セグメント情報等、連結財務諸表
| 科目 | 年度 | 育薬事業 | CRO事業 |
|---|---|---|---|
| 売上高 | 2013/03 | - | 34.3億 |
| 2014/03 | - | 34.3億 +0.1% | |
| 2015/03 | 3.65億 | 45.1億 +31.3% | |
| 2016/03 | 5.53億 +51.7% | 71.1億 +57.8% | |
| 2017/03 | 8.07億 +45.8% | 75.5億 +6.1% | |
| 2018/03 | 9.09億 +12.6% | 82億 +8.7% | |
| 2019/03 | 9.54億 +5% | 104億 +26.3% | |
| 2020/03 | 10.3億 +8.2% | 99億 -4.4% | |
| 2021/03 | 9.49億 -8% | 93.3億 -5.8% | |
| 2022/03 | 9.4億 -1% | 106億 +13.8% | |
| 2023/03 | 8.47億 -9.8% | 117億 +9.9% | |
| 2024/03 | 7.61億 -10.2% | 115億 -1.1% | |
| 2025/03 | 5.16億 -32.2% | 99.2億 -14.1% | |
| 科目 | 年度 | 育薬事業 | CRO事業 |
| 営業利益 | 2013/03 | - | 14.4億 |
| 2014/03 | - | 11.1億 -22.8% | |
| 2015/03 | 111百万 | 13.7億 +22.7% | |
| 2016/03 | 208百万 +87.6% | 27.4億 +100.5% | |
| 2017/03 | 293百万 +40.7% | 28.9億 +5.4% | |
| 2018/03 | 288百万 -1.7% | 27.2億 -5.9% | |
| 2019/03 | 314百万 +9% | 25.4億 -6.6% | |
| 2020/03 | 368百万 +17.4% | 22.5億 -11.5% | |
| 2021/03 | 248百万 -32.8% | 17.7億 -21.4% | |
| 2022/03 | 276百万 +11.6% | 25.4億 +43.8% | |
| 2023/03 | 159百万 -42.6% | 30.9億 +21.9% | |
| 2024/03 | 149百万 -6% | 27.2億 -12.2% | |
| 2025/03 | -66百万 赤字 | 15億 -44.8% | |
| 科目 | 年度 | 育薬事業 | CRO事業 |
| 営業利益率 | 2013/03 | - | 42.1% |
| 2014/03 | - | 32.5% -9.6% | |
| 2015/03 | 30.4% | 30.3% -2.2% | |
| 2016/03 | 37.6% +7.2% | 38.6% +8.3% | |
| 2017/03 | 36.3% -1.3% | 38.3% -0.3% | |
| 2018/03 | 31.7% -4.6% | 33.2% -5.1% | |
| 2019/03 | 32.9% +1.2% | 24.5% -8.7% | |
| 2020/03 | 35.7% +2.8% | 22.7% -1.8% | |
| 2021/03 | 26.1% -9.6% | 18.9% -3.8% | |
| 2022/03 | 29.4% +3.3% | 23.9% +5% | |
| 2023/03 | 18.7% -10.7% | 26.5% +2.6% | |
| 2024/03 | 19.6% +0.9% | 23.5% -3% | |
| 2025/03 | -12.9% 赤字 | 15.1% -8.4% | |
| 科目 | 年度 | 育薬事業 | CRO事業 |
| 固定資産増加額 | 2013/03 | - | 0.06億 |
| 2014/03 | - | 1.58億 +999.99% | |
| 2015/03 | 3.3百万 | 17.1億 +980.7% | |
| 2016/03 | 2.9百万 -11.7% | 1.03億 -93.9% | |
| 2017/03 | 2.1百万 -29.3% | 0.55億 -46.4% | |
| 2018/03 | 4.6百万 +122.4% | 0.88億 +59.1% | |
| 2019/03 | 1百万 -77.2% | 1.47億 +66.3% | |
| 2020/03 | 2.2百万 +115.1% | 6.14億 +318.8% | |
| 2021/03 | 1.4百万 -36.6% | 0.65億 -89.3% | |
| 2022/03 | 3.6百万 +151% | 0.63億 -3% | |
| 2023/03 | - | 0.58億 -8.8% | |
| 2024/03 | 1.5百万 | 0.89億 +54.4% | |
| 2025/03 | 0.6百万 -58.9% | 1.06億 +18.7% | |
| 科目 | 年度 | 育薬事業 | CRO事業 |
| 従業員数 | 2013/03 | - | - |
| 2014/03 | - | - | |
| 2015/03 | - | - | |
| 2016/03 | - | - | |
| 2017/03 | - | - | |
| 2018/03 | - | - | |
| 2019/03 | 54 | 651 | |
| 2020/03 | 61 +13% | 673 +3.4% | |
| 2021/03 | 45 -26.2% | 679 +0.9% | |
| 2022/03 | 43 -4.4% | 661 -2.7% | |
| 2023/03 | 34 -20.9% | 587 -11.2% | |
| 2024/03 | 24 -29.4% | 506 -13.8% | |
| 2025/03 | 24 ±0% | 450 -11.1% | |
| 科目 | 年度 | 育薬事業 | CRO事業 |
| 平均臨時雇用人員 | 2013/03 | - | - |
| 2014/03 | - | - | |
| 2015/03 | - | - | |
| 2016/03 | - | - | |
| 2017/03 | - | - | |
| 2018/03 | - | - | |
| 2019/03 | 0 | 39 | |
| 2020/03 | 0 | 18 -53.8% | |
| 2021/03 | 0 | 11 -38.9% | |
| 2022/03 | 0 | 12 +9.1% | |
| 2023/03 | 0 | 18 +50% | |
| 2024/03 | 0 | 27 +50% | |
| 2025/03 | 1 | 30 +11.1% | |
| 科目 | 年度 | 育薬事業 | CRO事業 |
| 資産 | 2013/03 | - | 5.54億 |
| 2014/03 | - | 7.69億 +38.9% | |
| 2015/03 | 141百万 | 33.2億 +332.1% | |
| 2016/03 | 177百万 +25.3% | 35.6億 +7.2% | |
| 2017/03 | 233百万 +31.2% | 30億 -15.9% | |
| 2018/03 | 137百万 -41.1% | 32.7億 +9.1% | |
| 2019/03 | 243百万 +77.7% | 71.6億 +119% | |
| 2020/03 | 510百万 +109.7% | 76.7億 +7.2% | |
| 2021/03 | 485百万 -4.9% | 85.9億 +12% | |
| 2022/03 | 373百万 -23.1% | 83.4億 -2.9% | |
| 2023/03 | 390百万 +4.6% | 93.5億 +12.1% | |
| 2024/03 | 391百万 +0.2% | 99.4億 +6.3% | |
| 2025/03 | 318百万 -18.7% | 85.8億 -13.7% | |
| 科目 | 年度 | 育薬事業 | CRO事業 |
| のれん | 2013/03 | - | - |
| 2014/03 | - | 1.37億 | |
| 2015/03 | - | 15.1億 +999.99% | |
| 2016/03 | - | 12.1億 -19.6% | |
| 2017/03 | - | 10.5億 -13.4% | |
| 2018/03 | - | 10.5億 -0.1% | |
| 2019/03 | - | 42.3億 +303.7% | |
| 2020/03 | - | 38.3億 -9.5% | |
| 2021/03 | - | 34.6億 -9.6% | |
| 2022/03 | - | 34.1億 -1.6% | |
| 2023/03 | - | 33.8億 -0.7% | |
| 2024/03 | - | 35.5億 +4.8% | |
| 2025/03 | - | 31.4億 -11.4% | |
| 科目 | 年度 | 育薬事業 | CRO事業 |
| のれん償却額 | 2013/03 | - | - |
| 2014/03 | - | - | |
| 2015/03 | - | 49百万 | |
| 2016/03 | - | 100百万 +101.7% | |
| 2017/03 | - | 89百万 -10.1% | |
| 2018/03 | - | 97百万 +8.2% | |
| 2019/03 | - | 318百万 +228.7% | |
| 2020/03 | - | 282百万 -11.5% | |
| 2021/03 | - | 228百万 -19.1% | |
| 2022/03 | - | 272百万 +19.2% | |
| 2023/03 | - | 319百万 +17.3% | |
| 2024/03 | - | 347百万 +9% | |
| 2025/03 | - | 368百万 +6% |
セグメント四半期
| 科目 | 年度 | 1Q | 2Q | 3Q | 4Q | 通期 |
|---|---|---|---|---|---|---|
| 育薬事業 | ||||||
| 売上高 1Q2Q 3Q | 2015/03 | 0.78億 | 0.81億 | 1.06億 | 0.99億 | 3.65億 |
| 2016/03 | 1.03億 +31.5% | 1.51億 +85.6% | 1.43億 +34.4% | 1.57億 +58.2% | 5.53億 +51.7% | |
| 2017/03 | 1.53億 +48.8% | 1.8億 +19.5% | 2.37億 +66% | 2.37億 +50.6% | 8.07億 +45.8% | |
| 2018/03 | 2.18億 +42.8% | 2.07億 +15.2% | 2.26億 -4.8% | 2.57億 +8.8% | 9.09億 +12.6% | |
| 2019/03 | 2.67億 +22.4% | 2.29億 +10.2% | 2.6億 +15% | 1.99億 -22.6% | 9.54億 +5% | |
| 2020/03 | 1.82億 -31.9% | 2.6億 +13.6% | 2.92億 +12.4% | 2.99億 +50% | 10.3億 +8.2% | |
| 2021/03 | 2.59億 +42.4% | 2.64億 +1.8% | 2.24億 -23.4% | 2.02億 -32.3% | 9.49億 -8% | |
| 2022/03 | 1.93億 -25.5% | 1.91億 -27.7% | 3.28億 +46.5% | 2.28億 +12.6% | 9.4億 -1% | |
| 2023/03 | 2.48億 +28.6% | 2.04億 +6.7% | 1.9億 -41.9% | 2.05億 -10.1% | 8.47億 -9.8% | |
| 2024/03 | 1.9億 -23.4% | 1.92億 -6% | 1.84億 -3.2% | 1.95億 -4.8% | 7.61億 -10.2% | |
| 営業利益 1Q2Q 3Q | 2015/03 | 8.1百万 | 31百万 | 39百万 | 33百万 | 111百万 |
| 2016/03 | 22百万 +173.3% | 87百万 +183.4% | 38百万 -3.3% | 62百万 +84.3% | 208百万 +87.6% | |
| 2017/03 | 32百万 +44.8% | 83百万 -4.8% | 89百万 +138% | 89百万 +44.4% | 293百万 +40.7% | |
| 2018/03 | 56百万 +76.6% | 86百万 +3.2% | 60百万 -33% | 86百万 -2.8% | 288百万 -1.7% | |
| 2019/03 | 83百万 +47.9% | 99百万 +15.3% | 87百万 +45.9% | 45百万 -48.4% | 314百万 +9% | |
| 2020/03 | 30百万 -63.8% | 137百万 +38.5% | 135百万 +54.7% | 66百万 +49.3% | 368百万 +17.4% | |
| 2021/03 | 41百万 +35.3% | 112百万 -18.2% | 32百万 -76.1% | 63百万 -5.6% | 248百万 -32.8% | |
| 2022/03 | 41百万 -0.5% | 85百万 -23.6% | 106百万 +229.6% | 44百万 -29.9% | 276百万 +11.6% | |
| 2023/03 | 79百万 +94.2% | 85百万 -0.4% | 69百万 -35.6% | -74百万 赤字 | 159百万 -42.6% | |
| 2024/03 | 38百万 -52.4% | 72百万 -15.7% | -1.3百万 赤字 | 41百万 | 149百万 -6% | |
| 営業利益率 | 2015/03 | 10.3% | 37.9% | 36.5% | 33.6% | 30.4% |
| 2016/03 | 21.5% +11.2% | 57.8% +19.9% | 26.3% -10.2% | 39.2% +5.6% | 37.6% +7.2% | |
| 2017/03 | 20.9% -0.6% | 46.1% -11.7% | 37.6% +11.3% | 37.5% -1.7% | 36.3% -1.3% | |
| 2018/03 | 25.9% +5% | 41.3% -4.8% | 26.5% -11.1% | 33.5% -4% | 31.7% -4.6% | |
| 2019/03 | 31.2% +5.3% | 43.2% +1.9% | 33.6% +7.1% | 22.3% -11.2% | 32.9% +1.2% | |
| 2020/03 | 16.6% -14.6% | 52.6% +9.4% | 46.2% +12.6% | 22.2% -0.1% | 35.7% +2.8% | |
| 2021/03 | 15.8% -0.8% | 42.3% -10.3% | 14.4% -31.8% | 31% +8.8% | 26.1% -9.6% | |
| 2022/03 | 21.1% +5.3% | 44.7% +2.4% | 32.4% +18% | 19.3% -11.7% | 29.4% +3.3% | |
| 2023/03 | 31.8% +10.7% | 41.8% -2.9% | 36% +3.6% | -36.1% 赤字 | 18.7% -10.7% | |
| 2024/03 | 19.8% -12% | 37.4% -4.4% | -0.7% 赤字 | 21% | 19.6% +0.9% | |
| 科目 | 年度 | 1Q | 2Q | 3Q | 4Q | 通期 |
| CRO事業 | ||||||
| 売上高 1Q2Q 3Q | 2014/03 | 8.1億 | 7.99億 | 9.04億 | 9.2億 | 34.3億 |
| 2015/03 | 9.71億 +19.8% | 8.78億 +9.9% | 10.7億 +18.4% | 15.9億 +72.6% | 45.1億 +31.3% | |
| 2016/03 | 16.2億 +67.3% | 19億 +116.8% | 18.1億 +69.1% | 17.8億 +11.9% | 71.1億 +57.8% | |
| 2017/03 | 18億 +10.8% | 19億 -0.3% | 19.3億 +6.7% | 19.2億 +8.1% | 75.5億 +6.1% | |
| 2018/03 | 19.2億 +6.7% | 19.8億 +4.1% | 21.7億 +12.2% | 21.4億 +11.6% | 82億 +8.7% | |
| 2019/03 | 24.9億 +29.9% | 26.2億 +32.9% | 27億 +24.7% | 25.4億 +18.5% | 104億 +26.3% | |
| 2020/03 | 25億 +0.2% | 24.5億 -6.7% | 25.2億 -6.6% | 24.3億 -4.3% | 99億 -4.4% | |
| 2021/03 | 21.7億 -13.3% | 22.9億 -6.4% | 23.3億 -7.8% | 25.4億 +4.7% | 93.3億 -5.8% | |
| 2022/03 | 25.9億 +19.7% | 25.5億 +11% | 27.6億 +18.8% | 27.1億 +6.6% | 106億 +13.8% | |
| 2023/03 | 26.2億 +1.1% | 28.5億 +11.8% | 31.4億 +13.5% | 30.7億 +13% | 117億 +9.9% | |
| 2024/03 | 28.9億 +10.3% | 27.9億 -2% | 30億 -4.3% | 28.6億 -6.6% | 115億 -1.1% | |
| 営業利益 1Q2Q 3Q | 2014/03 | 1.94億 | 3.34億 | 2.86億 | 3.01億 | 11.1億 |
| 2015/03 | 2.21億 +14.2% | 3億 -10.1% | 2.96億 +3.5% | 5.5億 +83.1% | 13.7億 +22.7% | |
| 2016/03 | 4.89億 +120.7% | 9.76億 +225.5% | 6.45億 +117.6% | 6.33億 +15.1% | 27.4億 +100.5% | |
| 2017/03 | 5.7億 +16.6% | 9.34億 -4.3% | 7.21億 +11.8% | 6.67億 +5.3% | 28.9億 +5.4% | |
| 2018/03 | 4.92億 -13.6% | 7.9億 -15.4% | 7.49億 +3.9% | 6.91億 +3.6% | 27.2億 -5.9% | |
| 2019/03 | 3.69億 -25% | 9.6億 +21.6% | 6.08億 -18.8% | 6.03億 -12.6% | 25.4億 -6.6% | |
| 2020/03 | 4.95億 +33.9% | 6.85億 -28.6% | 5.58億 -8.2% | 5.1億 -15.5% | 22.5億 -11.5% | |
| 2021/03 | 2.01億 -59.3% | 5.56億 -18.8% | 4億 -28.3% | 6.08億 +19.3% | 17.7億 -21.4% | |
| 2022/03 | 5.66億 +180.9% | 6.25億 +12.3% | 6.66億 +66.3% | 6.82億 +12.3% | 25.4億 +43.8% | |
| 2023/03 | 3.77億 -33.4% | 6.38億 +2% | 7.93億 +19.1% | 12.9億 +88.6% | 30.9億 +21.9% | |
| 2024/03 | 6.23億 +65.2% | 7.6億 +19.1% | 7.48億 -5.7% | 5.88億 -54.3% | 27.2億 -12.2% | |
| 営業利益率 | 2014/03 | 23.9% | 41.7% | 31.7% | 32.7% | 32.5% |
| 2015/03 | 22.8% -1.1% | 34.1% -7.6% | 27.7% -4% | 34.6% +1.9% | 30.3% -2.2% | |
| 2016/03 | 30.1% +7.3% | 51.3% +17.2% | 35.6% +7.9% | 35.6% +1% | 38.6% +8.3% | |
| 2017/03 | 31.7% +1.6% | 49.2% -2.1% | 37.3% +1.7% | 34.7% -0.9% | 38.3% -0.3% | |
| 2018/03 | 25.7% -6% | 40% -9.2% | 34.6% -2.7% | 32.2% -2.5% | 33.2% -5.1% | |
| 2019/03 | 14.8% -10.9% | 36.6% -3.4% | 22.5% -12.1% | 23.8% -8.4% | 24.5% -8.7% | |
| 2020/03 | 19.8% +5% | 28% -8.6% | 22.1% -0.4% | 21% -2.8% | 22.7% -1.8% | |
| 2021/03 | 9.3% -10.5% | 24.3% -3.7% | 17.2% -4.9% | 23.9% +2.9% | 18.9% -3.8% | |
| 2022/03 | 21.8% +12.5% | 24.5% +0.2% | 24.1% +6.9% | 25.1% +1.2% | 23.9% +5% | |
| 2023/03 | 14.4% -7.4% | 22.4% -2.1% | 25.3% +1.2% | 42% +16.9% | 26.5% +2.6% | |
| 2024/03 | 21.5% +7.1% | 27.2% +4.8% | 24.9% -0.4% | 20.5% -21.5% | 23.5% -3% | |
10年以上蓄積したファイナンスデータとAIを掛け合わせて、投資の意思決定を加速させるポジションです。
